SEPTODONT ACQUIRES ORAVERSE®, ANESTHETIC REVERSAL DRUG

SEPTODONT ACQUIRES ORAVERSE®

LANCASTER, PENNSYLVANIA, MARCH 18, 2011:

Septodont, the global leader in providing innovative, safe and effective solutions for dentistry worldwide, announces the purchase of OraVerse® from Novalar Pharmaceuticals, Inc. of San Diego, California. OraVerse is a unique anesthesia reversal agent, used when dentists or dental patients desire a quick return of sensation to the lip and tongue following a dental procedure in which a local anesthetic was administered.

Under the terms of sale, Septodont will assume full responsibility for OraVerse including sales, marketing and regulatory activities for the North American and unpartnered International markets.

As the leading global manufacturer of dental anesthetics, Septodont is well equipped with the resources to expand the market for OraVerse by targeting both the dental and patient communities. Septodont’s sales and marketing resources and their well established channel of dental distributors will allow greater access to the product throughout the world.

“Septodont has a long history of excellence in our manufacturing and distribution of safe and effective dental solutions to the dental professional, including Septocaine, the number one branded dental product in the USA. This acquisition is another opportunity to provide a product which will benefit both the dentist and the patient in its safety and convenience.” said Kent Chiu, President of Septodont North America. “It is a natural extension to our entire pain control category and an opportunity to provide a beneficial new solution to the patient after a dental procedure.”

“Novalar was responsible for the development, regulatory approval and, in 2009, commercial launch of the first anesthesia reversal agent in the US. I am proud of Novalar’s significant accomplishments and feel confident that now is the right time to place OraVerse in the hands of a company like Septodont, with a broad marketing reach and a complementary portfolio, which will enable the product to reach its full potential” said Donna Janson, President and CEO of Novalar.

OraVerse will be available through authorized dental supply dealers.
For more information call 800-872-8305, or visit our website at www.septodontusa.com.

About Septodont Septodont is a dental pharmaceutical company that specializes in innovative, safe and effective solutions for dentistry worldwide.

Contact:

Paul Mondock
Vice President, Sales and Marketing
Septodont
pmondock@septodontna.com
(717) 286-0110

About OraVerse®

OraVerse is a breakthrough that reverses unwanted lingering numbness after routine dental procedures where a local anesthetic containing a vasoconstrictor was used. OraVerse is indicated for reversal of the soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse is not recommended for use in children less than 6 years old or weighing less than 15 kg (33 lbs).

In clinical trials, the most common adverse events with OraVerse (phentolamine mesylate) vs. control were post procedural pain (6% vs. 6%), injection site pain (5% vs. 4%), tachycardia (5% vs. 6%), bradycardia (2% vs. 0.3%) and headache (3% vs. 4%). Following parenteral use of phentolamine in non-dental indications, myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents.

See full prescribing information – for details go to www.oraverse.com.